Real Life Experience Survey of Dupilumab in the Netherlands

CompletedOBSERVATIONAL

Enrollment

120

Participants

Timeline

Start Date

April 1, 2021

Primary Completion Date

October 30, 2022

Study Completion Date

December 31, 2022

Conditions

Severe Asthma

Interventions

DRUG

Dupilumab

start medication in cohort

Trial Locations (1)

Franciscus Gasthuis & Vlietland, Rotterdam

All Listed Sponsors

collaborator

Genzyme, a Sanofi Company

INDUSTRY

lead

Gert-Jan Braunstahl

OTHER

NCT05331755 - Real Life Experience Survey of Dupilumab in the Netherlands | Biotech Hunter | Biotech Hunter